Torc Investments and Research Initiates Coverage of Generex Biotechnology With a Buy Rating and 12-Month Price Target (RedNova)
Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that Torc Investments and Research LLC, a NASD registered broker-dealer, initiated research coverage of the Company today with a Buy rating and a 12-month price target of $3-$3.50.

Balancing Compliance with Economics: The New Role of Manufacturing (Logistics Management)
Continuing pressures on life sciences manufacturing, from increased competition to expiring patents, are forcing organizations to achieve tighter operating efficiencies, while improving their ability to satisfy quality compliance standards.

Matritech Notified by AMEX of Continued Listing Standards Non-Compliance (Business Wire via Yahoo! Finance)
NEWTON, Mass.----Matritech , a leading marketer and developer of protein-based diagnostic products for the early detection of cancer, today reported that on September 21, 2006 it received a letter from the American Stock Exchange stating that AMEX has determined that the Company is not in compliance with certain continued listing standards including Section 1003 of the Company Guide with